09.21.26 -- CDMO Market Risk Report: Tracking Client M&A, Approvals, And FDA Rejections

Cell and gene therapy programs require integrated development and manufacturing to overcome scientific, regulatory, and production challenges. End-to-end capabilities spanning process development, analytical testing, GMP manufacturing, and viral vector platforms help accelerate timelines while ensuring quality and compliance. Advanced technologies, flexible infrastructure, and global regulatory expertise support scalable clinical and commercial success. Coordinated solutions streamline development, strengthen program continuity, and help bring innovative therapies to patients more efficiently.

Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.